The National Football League Alumni Association (NFL Alumni) and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control have expanded the "GEAR UP Against ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

Zoldonrasib is an innovative tri-complex inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the active, oncogenic RAS G12D (ON) mutant. Revolution ...

January is national radon action month, and the city of Aspen and Pitkin County are offering all residents free radon test ...

GSK licenses Noetik’s AI foundation models in anchor partnership to transform cancer therapeutic research and development ...

Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...